Pharmacogenetics and Inflammatory Bowel Diseases in Adults and Children: Diagnosis and Treatment Prospects

The article highlights modern concepts of inflammatory diseases in adults and children in terms of genetic possibilities for diagnosing Crohn's disease and ulcerative colitis. It names the main candidate genes, which, in the presence of their specific polymorphisms, indicate the occurrence of a high risk of inflammatory bowel disease. The principles of modern therapy, the possibilities of pharma-cogenetic testing in predicting the effectiveness or risks of reducing the safety of drug therapy are described. The article focuses on modern trends and perspectives in ulcerative colitis and Crohn's disease treatment.

inflammatory bowel disease, ulcerative colitis, Crohn's disease, pharmacogenetics, polymorphisms, 5-ASA, mesalazine, immunomodulators, glucocorticosteroids, monoclonal antibodies, 5-АСК

1. Burisch J. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population based inception cohort. Dan Med J 2014; 61 (1): B4778.

2. Manninen P. Inflammatory Bowel Diseases. An epidemiological survey with twenty-year follow-up. Academic dissertation. Tampere University Press. 121.

3. Mamula P., Markowitz J., Baldassano R.N. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin N Am 2003; 32: 967-995.

4. Яблокова Е.А., Горелов А.В., Чумакова О.В. и др. Нарушение минерализации костной ткани у детей с воспалительными заболеваниями кишечника. Вопросы современной педиатрии 2006; 5 (4): 56-61.

5. Orel R. Inflammatory bowel disease, intestinal microflora, prebiotics and probiotics. International Journal of Sanitary Engineering Research 2009; 3 (1): 36-48.

6. Габрусская Т.В. Генетические маркеры воспалительных заболеваний кишечника: роль в патогенезе. Гастроэнтерология Санкт-Петербурга 2009; 4: 7-10.

7. Гастроэнтерология и гепатология: учебное пособие / С.С. Бацков; под редакцией С.С. Алексанина; Всерос центр экстрен и радиац медицины им. А.М.Никифорова МЧС России. СПб.: Политехник 2014; 260

8. Zeissig S., Burgel N., Gunzel D. et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007; 56: 61-72.

9. Lees C.W., Satsangi J.Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009; 3 (5): 513-534.

10. Actis G.C. The Changing Face of Inflammatory Bowel Disease: Etiology, Physiopathology, Epidemiology. Ann Colorectal Res 2016; 4 (1): e32942.

11. Щукина О.Б. Факторы прогноза болезни Крона. Альманах клинической медицины 2014; 3 (33): 3-14. / Shhukina O.B. Faktory prognoza bolezni Krona. Al'manakh klinicheskoj mediciny 2014; 3 (33): 3-14.

12. Von Stein P.L., Lofberg R., Kuznetsov N.V. et al. Multigene analysis can discriminate ulcerative colitis, Crohn's disease and irritable bowel syndrome. Gastroenterol 2008; 134: 1869-81.

13. Peloquin J.M., Goel G., Kong L. et al. Characterization of candidate genes in inflammatory bowel disease-associated risk loci. JCI Insight 2016; 1 (13): e87899.

14. Аляутдин P.H., Романов Б.К.Доза определяет яд. Безопасность и риск фармакотерапии 2014; 3 (4): 5-10. / Aljautdin R.N., Romanov B.K. Doza opredeljaet jad. Bezopasnost' i risk farmakoterapii 2014; 3 (4): 5-10. [in Russian]

15. Pithadia A.B., Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacological Reports 2011; 63: 629-642.

16. Hein D.W., Doll M.A., Fretland A.J. et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000; 9: 29-42.

17. Pierik M., Rutgeerts P., Vietinck R., Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12 (23): 3657-3667.

18. Mwinyi J. Pharmacogenetics of nuclear receptors and drug transporters in inflammatory bowel disease and hepatic drug metabolism. University of Zurich, Faculty of Medicine. 2013.

19. Кукес В.Г., Сычев Д.А., Бруслик Т. и др. Изучение транспортёров лекарственных средств как новая возможность персонализации фармакотерапии. Врач 2007; 5: 2-6.

20. Khan K.J.; Ullman T.A.; Ford A.C. et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterology 2011; 106 (4): 661-673.

21. Журавлева М.В., Кукес В.Г., Прокофьев А.Б., Архипов В.В. и др. Эффективность и безопасность применения лекарственных средств: значение и возможности клинической фармакологии. Ведомости НЦЭСМП 2015; 2: 20-24.

22. Корниенко Е.А., Крупина A.H., Габрусская Т.В., Калинина Н.М. Воспалительные заболевания кишечника с очень ранним началом. Альманах клин медицины 2016; 44 (6): 719-733

23. Uhlig H.H, Schwerd T., Koletzko S. et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014; 147 (5): 990-1007